Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by 2033

The new report published by The Business Research Company, titled Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the chemotherapy induced peripheral neuropathy treatment market size has grown strongly in recent years. It will grow from $1.54 billion in 2023 to $1.65 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The chemotherapy induced peripheral neuropathy treatment market size is expected to see strong growth in the next few years. It will grow to $2.25 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=11967&type=smp

Rising Cancer Prevalence Boosts Chemotherapy-Induced Peripheral Neuropathy Treatment Market
The increasing prevalence of cancer is expected to propel the growth of the chemotherapy-induced peripheral neuropathy treatment market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. Chemotherapy-induced peripheral neuropathy is a potential side effect of certain chemotherapy drugs used in the treatment of cancer. The chemotherapy-induced peripheral neuropathy treatment market is subjected to grow as there is a rise of cancer cases globally. For instance, in January 2023, according to the report published by the American Cancer Society, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the increasing prevalence of cancers driving the growth of the chemotherapy-induced peripheral neuropathy treatment market.

Innovation In Chemotherapy-Induced Peripheral Neuropathy Treatment Market
Product Innovation is the key trend gaining popularity in the chemotherapy-induced peripheral neuropathy treatment market. Major companies involved in the chemotherapy-induced peripheral neuropathy treatment market are focused on innovating new products to improve their observation power and sustain their position in the market. For instance, in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, disclosed the FDA's approval of the Investigational New Drug Application (IND) for ATX01, their Phase 2 first-in-class candidate. This innovative treatment is intended for individuals with erythromelalgia. Meanwhile, the first patients in the ATX01 for the Pain of Chemotherapy (ACT) study of chemotherapy-induced peripheral neuropathy (CIPN) have been randomized. The FDA has given both programs fast-track designation.

The chemotherapy induced peripheral neuropathy treatment market covered in this report is segmented -

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes
2) By Treatment: Medication, Therapy, Other Treatments
3) By Drug Type: Branded, Generic
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Research Institutes, Specialty Clinics

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=11967&type=discount

Major companies operating in the chemotherapy induced peripheral neuropathy treatment market report are Sanofi SA, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical Company, Amgen Inc., Asahi Kasei Pharma Corporation, Toray Industries , Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., BioMérieux SA, Jazz Pharmaceuticals Inc., WEX Pharmaceuticals Inc., Quidel Corporation, Laboratories Dr. Esteve S.A. (ESTEVE), Genentech Inc., MediciNova Inc., ChromaDex Corp, WinSanTor Inc., Solasia Pharma K.K., NeuroMetrix Inc., Nemus Bioscience Inc., Aphios Corporation, Kineta Inc., DARA BioSciences Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., Krenitsky Pharmaceuticals Inc.

Contents of the report:
1. Executive Summary
2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Report Structure
3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies
4. Chemotherapy Induced Peripheral Neuropathy Treatment Market - Macro Economic Scenario
5. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size And Growth
…..
27. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-peripheral-neuropathy-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.